| Trial ID: | L6595 |
| Source ID: | NCT00693771
|
| Associated Drug: |
Insulin Glargine
|
| Title: |
Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin
|
| Acronym: |
OPTIMIZATION
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Insulin Glargine
|
| Outcome Measures: |
Primary: HbA1c values, At baseline and 16 weeks | Secondary: Adverse events including hypoglycemia, From the beginning to the end of the study
|
| Sponsor/Collaborators: |
Sponsor: Sanofi
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
313
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2008-04
|
| Completion Date: |
2009-07
|
| Results First Posted: |
|
| Last Update Posted: |
2011-01-25
|
| Locations: |
Sanofi-Aventis Administrative Office, Shanghai, China
|
| URL: |
https://clinicaltrials.gov/show/NCT00693771
|
